×
Immunovant EBITDA 2019-2024 | IMVT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Immunovant ebitda from 2019 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Immunovant EBITDA 2019-2024 | IMVT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Immunovant ebitda from 2019 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$171.8B
Vertex Pharmaceuticals (VRTX)
$117.5B
Regeneron Pharmaceuticals (REGN)
$111.6B
Bristol Myers Squibb (BMY)
$109.4B
Gilead Sciences (GILD)
$105.3B
CSL (CSLLY)
$95.7B
GSK (GSK)
$80.5B
Alnylam Pharmaceuticals (ALNY)
$34.4B
Argenex SE (ARGX)
$31.7B
BioNTech SE (BNTX)
$29.2B
Biogen (BIIB)
$27B
BeiGene (BGNE)
$23.9B
Moderna (MRNA)
$23.1B
Illumina (ILMN)
$22.5B
Genmab (GMAB)
$15.5B
BioMarin Pharmaceutical (BMRN)
$13.2B
Incyte (INCY)
$13B
Exact Sciences (EXAS)
$12.6B
Vaxcyte (PCVX)
$12.4B
Insmed (INSM)
$12.4B
Bio-Techne Corp (TECH)
$11.9B
Sarepta Therapeutics (SRPT)
$11.5B
QIAGEN (QGEN)
$9.9B
Bio-Rad Laboratories (BIO.B)
$9.3B
Legend Biotech (LEGN)
$8.9B
Roivant Sciences (ROIV)
$8.4B
Ascendis Pharma (ASND)
$8.3B
Revolution Medicines (RVMD)
$7.9B
Intra-Cellular Therapies (ITCI)
$7.7B
Repligen (RGEN)
$7.7B